Khan Nedd, MD
Internal Medicine · Grand Rapids, MINPI 1043284219
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,490 of the $4,342 with a category attached, or 80.4%. 25 manufacturers reported payments, led by Biogen at 25.5% of the total. Reporting peaked in 2019 at $1,291 and has fallen 83.7% since, to $210 in 2025. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $33.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$1K
- GSK$549
- Johnson & Johnson$345
- Sanofi$278
- Pfizer$256
- Amgen$235
- plus $2K from 19 others
Across 443 payments — averaging $5039.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$762K
- Chiesi USA, Inc.$611K
- Takeda Pharmaceuticals U.S.A., Inc.$481K
- Viiv Healthcare Company$100K
- Sanofi US Services Inc.$76K
- Pfizer$48K
- plus $154K from 6 others
What the payments were for
- Consulting fees$75317%
- Food & beverage$3,49080%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 9 | $1,107 |
| GSK | 24 | $549 |
| Johnson & Johnson(2 entities) | 12 | $345 |
| Sanofi | 5 | $278 |
| Pfizer | 22 | $256 |
| Amgen(2 entities) | 7 | $235 |
| Genentech USA, Inc. | 8 | $225 |
| Merck | 4 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $164 |
| Gilead | 1 | $134 |
| Chiesi USA, Inc. | 2 | $117 |
| E.r. Squibb & Sons, L.L.C. | 6 | $105 |
| Grifols USA, LLC | 5 | $100 |
| Novartis | 5 | $99 |
| Sanofi-aventis U.S. LLC | 2 | $94 |
| AstraZeneca(2 entities) | 5 | $85 |
| Argenx US, Inc. | 1 | $56 |
| US Oncology Corporate, Inc. | 1 | $36 |
| Alkermes, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $19 |
| Mckesson Specialty Care Distribution, LLC | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,342 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GalafoldMigalastat Hcl | 26 | $825,328 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Grand Rapids
- Robert SelfeGrand Rapids$238K
- Celia EganGrand Rapids$54K
- Jeremy GentileGrand Rapids$44K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.